Radiofrequency Ablation: A Safe, Effective Treatment for Thyroid Cancer in the "Danger Triangle" Area

Table of Contents

• Key Points
• Understanding Thyroid Cancer and the "Danger Triangle"
• How the Study Was Conducted
• Who Was Included in the Study
• The RFA Procedure Explained
• Key Findings: Tumor Shrinkage and Disappearance
• Disease Progression and Recurrence
• Complications and Safety Profile
• Clinical Implications: What This Means for Patients
• Study Limitations
• Recommendations for Patients
• Frequently Asked Questions
• Source Information

Key Points

• In a study of 94 patients with small papillary thyroid cancer in the danger triangle, radiofrequency ablation completely destroyed all tumors in one session.
• No local recurrences occurred over 36 months, and only 3.2% had mild voice changes that resolved within 4 months without treatment.
• Thyroid function remained stable after RFA, and no patients developed hypothyroidism, unlike with surgery.
• Tumors shrank gradually: the ablation zone first expanded, then shrank by 99% at 36 months; 76.6% of tumors disappeared completely.
• This was a single-center retrospective study; results may not apply to all patients, and longer-term data are needed.

Understanding Thyroid Cancer and the "Danger Triangle"

Papillary thyroid carcinoma (PTC) is the most common type of thyroid cancer, and many patients are diagnosed with small, early-stage tumors. Traditionally, surgery was the standard treatment, but recent advances in thermal ablation technologies — techniques that destroy tumors using heat — have given patients and doctors new options.

The 2021 European guidelines now recommend thermal ablation as an established approach for treating low-risk papillary thyroid microcarcinoma (PTMC, tumors measuring 1 centimeter or less) and for radioiodine-refractory metastases (cancer that no longer responds to radioactive iodine treatment). Several studies have also demonstrated that microwave ablation — a similar heat-based technique — is effective and safe for PTC lesions that invade or approach the thyroid capsule, the thin fibrous covering of the thyroid gland.

However, a particularly challenging situation arises when tumors are located in what doctors call the "danger triangle." This area is defined by three anatomical landmarks:

• The dorsal (back) edge of the thyroid gland
• The lateral (side) tracheal wall (the windpipe)
• The anterior (front) edge of the esophageal wall (the food pipe)

When PTC tumors are located within this danger triangle, there is very limited space available for ablation. The tumor sits close to the esophagus, trachea, and the thyroid capsule, which can make treatment technically challenging. This proximity increases the potential risks of nerve injury (particularly to the recurrent laryngeal nerve, which controls the vocal cords) and local tumor recurrence (the tumor coming back in the same spot).

"Despite these challenges, the most effective approach for managing PTC lesions within the danger triangle has remained undetermined," the study authors note. "No in-depth studies to date have systematically explored the safety, efficacy, and feasibility of radiofrequency ablation for tumors in this region." This study was designed to fill that gap and guide future clinical decision-making.

How the Study Was Conducted

This was a retrospective study, meaning researchers looked back at medical records of patients who had already been treated. The study was approved by the Ethics Committee of Fujian Provincial Hospital (approval number K2023-07017) and followed the principles of the Declaration of Helsinki, an international standard for ethical medical research. All patients provided written informed consent before receiving RFA treatment.

Between January 2018 and April 2020, clinical data were collected from 132 PTC patients with tumors located in the danger triangle who had undergone percutaneous RFA (RFA performed through the skin, without open surgery) at Fujian Provincial Hospital. After applying strict inclusion and exclusion criteria, 38 patients were excluded, leaving 94 patients (71.2% of the original 132) for analysis.

The patients were divided into two groups based on tumor size, using the standard TNM cancer staging system:

• T1a group: tumors measuring ≤ 1 centimeter (80 patients, 85.1%)
• T1b group: tumors measuring greater than 1 cm but ≤ 2 centimeters (14 patients, 14.9%)

All tumors were classified as T1N0M0 — this staging notation means the primary tumor is small (T1), there is no spread to lymph nodes (N0), and no distant metastasis (M0).

Who Was Included in the Study

Patients were eligible for the study if they met all of the following criteria:

1. They were not eligible for surgery or had refused to undergo surgery
2. They had PTC (or suspected PTC) up to 2 cm in size, diagnosed by fine-needle aspiration (FNA) or core needle biopsy
3. They had a single (unifocal) PTC tumor in the danger triangle area, no larger than 2.0 cm, located adjacent to or abutting the intact thyroid capsule, with the continuity of the capsule confirmed by ultrasound
4. Imaging confirmed no distant metastasis or lymph node metastasis (LNM)
5. They had no history of neck irradiation
6. They had at least 12 months of follow-up after RFA
7. They had normal vocal cord mobility, confirmed by flexible endoscopy before the procedure

Patients were excluded if they had a discontinuity of the adjacent thyroid capsule, tumors larger than 2.0 cm, multifocal PTC (more than one tumor), evidence of lymph node or distant metastasis, follow-up shorter than 12 months, other malignancies, renal failure, respiratory failure, severe cardiac failure, coagulatory disorders, or abnormal vocal cord mobility.

The mean age of the 94 enrolled patients was 44.45 ± 13.08 years. The group included 73 women (77.7%) and 21 men (22.3%) — reflecting the known higher incidence of thyroid cancer in women. Tumors were located in the right lobe of the thyroid in 53 patients (56.4%) and the left lobe in 41 patients (43.6%). The average follow-up duration was 29.06 ± 7.77 months.

Testing also revealed that 84 patients (89.4%) were positive for the BRAF V600E mutation, a genetic marker commonly associated with thyroid cancer, while 10 patients (10.6%) were negative for this mutation.

The Relationship Between Tumors and the Thyroid Capsule

Researchers carefully measured the distance between each PTC nodule and the thyroid capsule. "Adjacency" was defined as a distance greater than 0 mm but no more than 2 mm, while "abutting" meant the nodule touched the capsule at 0 mm distance without evidence of invasion into surrounding tissue.

Based on ultrasound views, the thyroid capsule within the danger triangle was divided into three zones:

• Posterior medial capsule: close to the retropharyngeal space (behind the throat) and tracheoesophageal groove (the groove between the windpipe and food pipe)
• Posterior capsule: close to the retropharyngeal space
• Medial capsule: close to the trachea (windpipe)

Of the 94 tumors, 16 (17%) were adjacent to the thyroid capsule — 13 classified as T1a and 3 as T1b. The remaining 78 tumors (83%) abutted the capsule — 67 T1a and 11 T1b tumors. Among these, 35 abutted only one side of the capsule (18 against the posterior capsule and 17 against the medial capsule), while 43 tumors abutted both the posterior and medial capsules simultaneously.

The RFA Procedure Explained

Radiofrequency ablation works by using high-frequency electrical currents to generate heat that destroys cancer cells. The procedure in this study used a monopolar RFA ablation needle with a 5 mm working electrode, specifically the Canwell Radiofrequency Ablation Device (model CRS2000, manufactured in Hangzhou, China).

Here is a step-by-step breakdown of how the procedure was performed:

1. Patient positioning: Patients lay on their back (supine position) with their necks extended.
2. Anesthesia: A local anesthetic called 1% lidocaine was injected to numb the neck area.
3. Fluid isolation (hydrodissection): A needle was inserted from the isthmus (the central bridge of the thyroid), and a 21-gauge needle was positioned into the posterior medial thyroid space — between the posterior medial thyroid capsule, esophagus, and recurrent laryngeal nerve. A continuous injection of 5% glucose solution was used to create a fluid barrier of at least 5 mm between the tumor and these critical structures. This protective fluid "cushion" minimizes the risk of thermal (heat) injury to the nerve, windpipe, and food pipe.
4. Ablation technique: Using a trans-isthmic approach (passing through the thyroid isthmus), the doctor performed a "moving ablation technique." The tumor tissue closest to the posterior capsule and trachea was ablated first, followed by superficial movement to treat the rest of the tumor.
5. Power settings: The initial power was set at a low 15 watts. If no transient hyperechoic region (an ultrasound sign that heating is occurring) appeared at the electrode tip within 5–10 seconds, the power was increased to 20 watts. Each site was ablated for 15 seconds before moving the needle to a non-ablated area.
6. Safety margin: To minimize the chance of residual tumor tissue or recurrence, the ablated area extended 3 mm beyond the tumor edge on all sides except the capsule side.
7. Verification: After ablation, contrast-enhanced ultrasound (CEUS) was performed to assess the ablation zone. If any abnormal enhancement (a sign of remaining live tissue) was detected, supplementary ablation was immediately performed.
8. Post-procedure monitoring: All patients were monitored in the hospital for 12 hours and assessed for any complications during and after the procedure.

The average ablation time for the entire procedure was 151.9 ± 75.3 seconds (range: 40–431 seconds). For T1a tumors, the average was 143.6 ± 74.5 seconds (range: 33–431 seconds), while for T1b tumors it was longer at 199.4 ± 63.5 seconds (range: 101–331 seconds). The average depth of the fluid isolation belt created by hydrodissection was 0.69 ± 0.15 cm.

Key Findings: Tumor Shrinkage and Disappearance

The most striking result of this study was the 100% technical success rate. Contrast-enhanced ultrasound performed immediately after ablation confirmed complete tumor ablation in all 94 patients.

Before the procedure, the mean maximum tumor diameter was 0.73 ± 0.34 cm (range: 0.24–2.0 cm), and the mean target lesion volume was 0.18 ± 0.27 ml (range: 0.02–0.78 ml).

After RFA, researchers tracked the size of the ablation zone (the area of dead tissue left behind by the heat) at 1, 3, 6, 12, 18, 24, 30, and 36 months. The changes followed a predictable pattern:

• 1 month after RFA: The ablation zone expanded — maximum diameter increased to 0.97 ± 0.38 cm and volume increased to 0.54 ± 0.83 ml, both significantly larger than the original tumor (p < 0.001).
• 3 months after RFA: The ablation zone remained enlarged — diameter 0.91 ± 0.39 cm and volume 0.23 ± 0.19 ml (still significantly larger than baseline, p < 0.001).
• 6 months after RFA: The ablation zone began shrinking back — diameter 0.64 ± 0.30 cm, which was no longer significantly different from the baseline tumor diameter (p = 0.053). Volume at 0.12 ± 0.16 ml was significantly reduced compared to baseline (p = 0.007).
• 12 months after RFA: Diameter 0.44 ± 0.24 cm, volume 0.04 ± 0.06 ml (p < 0.001).
• 18 months after RFA: Diameter 0.28 ± 0.21 cm, volume 0.01 ± 0.03 ml (p < 0.001).
• 24 months after RFA: Diameter 0.22 ± 0.21 cm, volume 0.013 ± 0.032 ml (p < 0.001).
• 30 months after RFA: Diameter 0.14 ± 0.17 cm, volume 0.005 ± 0.013 ml (p < 0.001).
• 36 months after RFA: Diameter 0.06 ± 0.12 cm, volume 0.001 ± 0.005 ml (p < 0.001).

The volume reduction ratio (VRR) — a measure of how much the treated area has shrunk relative to the original tumor — improved steadily at every follow-up point (p < 0.001 for all time points). At 36 months, the mean VRR reached 0.99 ± 0.01, meaning the treated area had shrunk by 99% compared with the original tumor volume.

By the final follow-up, 72 of 94 tumors (76.59%) had completely disappeared on ultrasound examination. However, there was a significant difference between the two groups:

• T1a tumors: 80% disappearance rate (64 of 80 tumors)
• T1b tumors: 57.1% disappearance rate (8 of 14 tumors)

This difference was statistically significant (p < 0.001). Kaplan-Meier analysis (a statistical method used to estimate the time until an event occurs) confirmed that T1a tumors disappeared significantly faster than T1b tumors, with a log-rank test value of 9.367 (p = 0.002). The median time to disappearance was 27 months for T1a tumors versus 30 months for T1b tumors.

Thyroid Function Remained Stable

An important safety finding was that RFA did not affect thyroid function. Researchers compared levels of key thyroid hormones before and one month after the procedure:

• T3 (triiodothyronine): 4.51 ± 0.67 before vs. 4.30 ± 0.62 after (p = 0.133 — not significant)
• T4 (thyroxine): 17.28 ± 2.44 before vs. 17.62 ± 3.11 after (p = 0.403 — not significant)
• TSH (thyroid-stimulating hormone): 2.33 ± 5.10 before vs. 2.36 ± 4.96 after (p = 0.953 — not significant)
• TGAb (thyroglobulin antibodies): 40.45 ± 98.30 before vs. 42.64 ± 103.42 after (p = 0.882 — not significant)

None of the patients developed hypothyroidism (underactive thyroid), which is a known risk of surgery. This suggests that RFA preserves the thyroid's ability to produce hormones.

Disease Progression and Recurrence

One of the most encouraging findings was the complete absence of local tumor recurrence — no tumors reappeared at the original treatment site during the entire 36-month follow-up period.

The overall disease progression rate (which includes new tumor formation, lymph node metastasis, local recurrence, and PTC-related death) was 3.2% (3 of 94 patients). All three cases occurred in the T1a subgroup (3 of 80, or 3.8%), while none occurred in the T1b subgroup (0 of 14, or 0%). This difference was not statistically significant (p > 0.05).

The three cases of disease progression were as follows:

1. Case 1: A patient developed a metastatic lymph node in the ipsilateral (same-side) neck at 6 months after RFA.
2. Case 2: A patient developed a new PTC nodule in the contralateral (opposite-side) thyroid lobe at 12 months after RFA.
3. Case 3: A patient developed an ipsilateral neck metastatic lymph node at 18 months after RFA.

All three patients with disease progression refused to undergo surgery, so additional ablation was performed to eradicate the new lesions. No further instances of recurrence or distant metastasis were observed in these patients during the remainder of the follow-up period. Notably, all primary nodules in the T1a patients who experienced progression were positive for the BRAF V600E mutation.

Looking at the location of the original tumors in these three patients: two had lesions adjacent to the posterior medial capsule, and one had a lesion at the medial capsule. None of the T1b patients experienced lymph node metastasis or new malignant thyroid nodules.

Complications and Safety Profile

The treatment was well tolerated by all participants, with no major complications reported. Specifically:

• No severe hematomas (collections of blood outside blood vessels)
• No skin burns
• No permanent hoarseness
• No hypothyroidism

The only complication observed was mild voice changes, which occurred in just 3 of 94 patients (3.2%). This included 2 patients in the T1a group and 1 patient in the T1b group — a difference that was not statistically significant (p > 0.05). The tumors in these three patients were located as follows:

• One abutted the posterior capsule of the left thyroid
• One abutted the posterior capsule of the right thyroid
• One abutted the posterior medial capsule of the right thyroid

Critically, all voice changes resolved completely within 4 months without any specific treatment. No patients required intervention for these symptoms.

The study authors compared this complication rate favorably with previously published rates for other treatment approaches: surgery has a reported complication rate of 7.1%, and microwave ablation has a rate of 6.0%. The 3.2% complication rate in this study is notably lower than both.

Clinical Implications: What This Means for Patients

This study provides strong evidence that RFA is a safe and effective treatment option for patients with solitary T1N0M0 PTC in the danger triangle area. For patients facing a thyroid cancer diagnosis in this challenging location, these findings offer several important takeaways:

• A non-surgical option exists: Patients who are not eligible for surgery or who wish to avoid it can consider RFA, even when tumors are located in a technically difficult area.
• Complete ablation is achievable: The 100% technical success rate demonstrates that with the right technique, even tumors in the danger triangle can be completely destroyed in a single session.
• Recurrence risk is low: With zero local recurrences in 36 months of follow-up, RFA appears to offer durable, long-lasting control of the treated tumor.
• Voice preservation is possible: The 3.2% rate of voice changes — all temporary — is reassuring for patients concerned about the recurrent laryngeal nerve, which sits close to the danger triangle.
• Thyroid function is preserved: Unlike surgery, which often requires lifelong thyroid hormone replacement, RFA kept thyroid hormone levels stable in all 94 patients.

The study authors attribute their success to several innovative aspects of their ablation strategy. First, the isthmus pathway for needle insertion allows continuous monitoring of the relationship between the electrode, target lesion, and the recurrent laryngeal nerve — a critical safety feature in the danger triangle. Second, the short active tip electrode generates a smaller, more easily controlled thermal field than conventional electrodes, reducing the risk of injury to normal tissue and nerves. Third, the combination of low power (15–20 watts) and fluid isolation (at least 5 mm of separation) provides an added layer of protection for nearby structures.

"Sufficient paratracheal fluid isolation combined with a low-power, short active tip radiofrequency ablation strategy is a safe and effective method for treating solitary T1N0M0 PTC in the danger triangle area," the authors concluded.

Study Limitations

While the results are encouraging, the study has several limitations that patients and doctors should keep in mind:

• Retrospective design: Because this study looked back at medical records rather than randomly assigning patients to different treatments, it cannot directly compare RFA against surgery or other ablation methods with the same scientific rigor as a randomized controlled trial.
• Single-center study: All patients were treated at one hospital in China, so the results may not be fully generalizable to other medical centers or populations.
• No control group: There was no comparison group of patients who underwent surgery or another treatment, making it difficult to definitively conclude that RFA is superior or equivalent.
• Relatively small sample size: The T1b subgroup had only 14 patients, which limits the statistical power to detect differences between T1a and T1b tumors.
• Limited follow-up duration: While 36 months of follow-up is meaningful, thyroid cancer can recur later, and longer-term data would provide additional confidence.
• Preliminary nature: The authors describe this as a "preliminary analysis," meaning further research is needed to confirm these findings on a larger scale.
• Selection bias: Since all patients either refused surgery or were not eligible for it, these results may not apply to all thyroid cancer patients.

Recommendations for Patients

Based on this research, patients diagnosed with small papillary thyroid carcinoma in the danger triangle area may want to consider the following:

1. Have a conversation about all treatment options: Surgery is still a standard and effective treatment for thyroid cancer. Ask your medical team whether you are a candidate for surgery, RFA, or active surveillance, and what the risks and benefits of each might be for your specific situation.
2. Ask about RFA specifically: If you have a solitary T1N0M0 PTC tumor (2 cm or smaller, no lymph node involvement, no distant spread) in the danger triangle area, RFA may be a viable option. This study suggests success rates are highest for tumors ≤1 cm (T1a), which had an 80% complete disappearance rate.
3. Choose an experienced center: The authors emphasize that their success depends on a specific technique — sufficient paratracheal fluid isolation with low-power, short active tip ablation. If you are considering RFA, ask whether the treating center has experience with this particular approach in the danger triangle area.
4. Expect a gradual improvement: Tumor shrinkage after RFA is not immediate. The ablation zone actually expands in the first 1–3 months before gradually shrinking. Complete tumor disappearance can take 27–30 months, so patience and consistent follow-up are essential.
5. Commit to regular follow-up: The study protocol included ultrasound exams at 1, 3, 6, 12, 18, 24, 30, and 36 months after ablation, plus annual chest CT scans. Regular monitoring is important to detect any new lesions or lymph node spread early and to confirm the treatment zone is shrinking as expected.
6. Be aware of the small risks: Mild voice changes can occur (3.2% in this study), but they typically resolve on their own within 4 months. If you experience hoarseness after RFA, let your doctor know so they can check your vocal cord function with flexible endoscopy.
7. Know your genetic marker status: The aggressive nature of BRAF V600E-positive tumors was not clearly associated with worse outcomes in this study, but it's still useful to know your tumor's genetic profile as part of your overall risk assessment.

Frequently Asked Questions

What is the 'danger triangle' in thyroid cancer?

The danger triangle is an area near the windpipe, food pipe, and vocal cord nerves. It is defined by the back edge of the thyroid gland, the side wall of the windpipe, and the front wall of the food pipe. Tumors here are hard to treat because there is little space and nearby nerves can be injured.

Who might be eligible for radiofrequency ablation (RFA) for thyroid cancer in the danger triangle?

In a study of 94 patients, those eligible had a single papillary thyroid cancer up to 2 cm in the danger triangle, no lymph node or distant spread, normal vocal cord movement, and either could not have surgery or chose not to. They also needed at least 12 months of follow-up. Your doctor can assess if you meet similar criteria.

What happens during the RFA procedure?

During RFA, you lie on your back with your neck extended. The neck is numbed with local anesthetic. A thin needle is inserted through the skin into the tumor. A fluid barrier is injected to protect nearby structures. Heat from radio waves destroys the cancer cells. The procedure typically takes a few minutes of active ablation time.

What are the risks or side effects of RFA for thyroid cancer in the danger triangle?

In a study of 94 patients, the only complication was mild voice changes in 3.2% of patients. These resolved within 4 months without treatment. No severe bleeding, skin burns, permanent hoarseness, or hypothyroidism occurred. The complication rate was lower than reported for surgery (7.1%) or microwave ablation (6.0%).

I have a small papillary thyroid carcinoma in the danger triangle area and was told I could have radiofrequency ablation instead of surgery — when should I get a second opinion?

A second opinion is worth considering when a solitary T1N0M0 papillary thyroid carcinoma up to 2 cm sits in the danger triangle, because treatment there is technically challenging and no established standard approach exists. It is especially relevant if you are not eligible for surgery or have refused it, since the reported outcomes come from patients in that situation. A review can confirm tumor size, capsule relationship, vocal cord function and BRAF V600E status, and clarify whether RFA or surgery fits. Diagnostic Detectives Network provides independent expert second opinions.

Source Information

Original article title: Radiofrequency ablation for solitary T1N0M0 papillary thyroid carcinoma in the danger triangle area a preliminary analysis

Authors: Dan-ling Zhang, Sheng Chen, Yuhan Qiu, Jian-chuan Yang, Zhiliang Hong, Jianwei Li, and Song-song Wu

Journal: International Journal of Hyperthermia, 2024, Volume 41, Issue 1, Article 2305256

DOI: 10.1080/02656736.2024.2305256

Published online: February 5, 2024

Affiliation: Department of Ultrasonography, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fujian, China; and Department of Ultrasonography, Fuzhou First General Hospital, Fuzhou, China

Funding/Open access: This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial License. Dan-ling Zhang and Sheng Chen contributed equally as co-first authors.

Note: This patient-friendly article is based on peer-reviewed research published in a reputable medical journal. It is intended for educational purposes and should not replace individualized medical advice from your healthcare provider. Always discuss your specific diagnosis and treatment options with your doctor.